{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:15:16Z","timestamp":1773213316976,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T00:00:00Z","timestamp":1506038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10067-017-3829-9","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T05:59:42Z","timestamp":1506059982000},"page":"181-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-3070","authenticated-orcid":false,"given":"Yosuke","family":"Hattori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daihei","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,22]]},"reference":[{"key":"3829_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094\u20131108","journal-title":"Lancet"},{"key":"3829_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/rheumatology\/38.11.1081","volume":"38","author":"MD Posthumus","year":"1999","unstructured":"Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA et al (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford) 38:1081\u20131087","journal-title":"Rheumatology (Oxford)"},{"key":"3829_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7","volume":"43","author":"H Yamanaka","year":"2000","unstructured":"Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A et al (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852\u2013858","journal-title":"Arthritis Rheum"},{"key":"3829_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","volume":"42","author":"MJ Green","year":"2003","unstructured":"Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D et al (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 42:83\u201388","journal-title":"Rheumatology (Oxford)"},{"key":"3829_CR5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5858\/2007-131-563-SLOMMS","volume":"131","author":"A Kobayashi","year":"2007","unstructured":"Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K et al (2007) Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 131:563\u2013570","journal-title":"Arch Pathol Lab Med"},{"key":"3829_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"P Garnero","year":"2010","unstructured":"Garnero P, Thompson E, Woodworth T, Smolen JS (2010) Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62:33\u201343","journal-title":"Arthritis Rheum"},{"key":"3829_CR7","doi-asserted-by":"publisher","first-page":"183653","DOI":"10.1155\/2013\/183653","volume":"2013","author":"MM Ally","year":"2013","unstructured":"Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R (2013) Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediat Inflamm 2013:183653","journal-title":"Mediat Inflamm"},{"key":"3829_CR8","doi-asserted-by":"publisher","first-page":"179284","DOI":"10.1155\/2014\/179284","volume":"2014","author":"JD Ma","year":"2014","unstructured":"Ma JD, Zhou JJ, Zheng DH, Chen LF, Mo YQ, Wei XN et al (2014) Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediat Inflamm 2014:179284","journal-title":"Mediat Inflamm"},{"key":"3829_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/s10165-007-0608-5","volume":"17","author":"M Shinozaki","year":"2007","unstructured":"Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N et al (2007) Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 17:403\u2013408","journal-title":"Mod Rheumatol"},{"key":"3829_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/1756-185X.12434","volume":"19","author":"SM Galil","year":"2016","unstructured":"Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE (2016) Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis 19:377\u2013384","journal-title":"Int J Rheum Dis"},{"key":"3829_CR11","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar3734","volume":"14","author":"M Houseman","year":"2012","unstructured":"Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I et al (2012) Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 14:R30","journal-title":"Arthritis Res Ther"},{"key":"3829_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13075-015-0803-2","volume":"17","author":"JD Ma","year":"2015","unstructured":"Ma JD, Wei XN, Zheng DH, Mo YQ, Chen LF, Zhang X et al (2015) Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther 17:289","journal-title":"Arthritis Res Ther"},{"key":"3829_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13075-016-0948-7","volume":"18","author":"K Shiozawa","year":"2016","unstructured":"Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S et al (2016) MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Arthritis Res Ther 18:55","journal-title":"Arthritis Res Ther"},{"key":"3829_CR14","first-page":"888","volume":"27","author":"C Ribbens","year":"2000","unstructured":"Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D et al (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27:888\u2013893","journal-title":"J Rheumatol"},{"key":"3829_CR15","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1007\/s00296-011-2256-5","volume":"32","author":"A Kaneko","year":"2012","unstructured":"Kaneko A, Kida D, Saito K, Tsukamoto M, Sato T (2012) Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int 32:3631\u20133637","journal-title":"Rheumatol Int"},{"key":"3829_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/14397595.2013.854079","volume":"24","author":"N Nishimoto","year":"2014","unstructured":"Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M et al (2014) Drug free REmission\/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 24:17\u201325","journal-title":"Mod Rheumatol"},{"key":"3829_CR17","doi-asserted-by":"publisher","unstructured":"Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T et al (2017) High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab. Mod Rheumatol. https:\/\/doi.org\/10.1080\/14397595","DOI":"10.1080\/14397595"},{"key":"3829_CR18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"3829_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/annrheumdis-2011-200108","volume":"71","author":"Y Urata","year":"2012","unstructured":"Urata Y, Uesato R, Tanaka D, Nakamura Y, Motomura S (2012) Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 71:534\u2013540","journal-title":"Ann Rheum Dis"},{"key":"3829_CR20","doi-asserted-by":"publisher","unstructured":"Hattori Y, Kida D, Kaneko A (2017) Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Mod Rheumatol. https:\/\/doi.org\/10.1080\/14397595","DOI":"10.1080\/14397595"},{"key":"3829_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/ard.61.2.161","volume":"61","author":"C Ribbens","year":"2002","unstructured":"Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161\u2013166","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3829-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T05:33:45Z","timestamp":1659504825000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3829-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3829-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,22]]},"assertion":[{"value":"21 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of our institute and was conducted from January through March 2013 in accordance with the Declaration of Helsinki. Patient anonymity was maintained during data collection, and security of personal information was strictly controlled. All patients gave their informed consent prior to their inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yosuke Hattori received grants from Pfizer and Janssen Pharma. Daihei Kida received grants from Towa Pharma Corporation and Chugai Pharma Corporation. Atsushi Kaneko received grants from Astellas Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}